1.Riddle, MS, et al. Incidence, etiology, and impact of diarrhea among long-term travelers (US military and similar populations): a systematic review. American Journal of Tropical Medicine and Hygiene 2006; 74: 891–900.
2.Kotloff, KL, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bulletin of the World Health Organization 1999; 77: 6516–66.
3.Shaughnessy, HJ, et al. Experimental human bacillary dysentery; polyvalent dysentery vaccine in its prevention. Journal of the American Medical Association 1946; 132: 362–368.
4.DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177–188.
5.Van de Verg, LL, et al. Cross-reactivity of Shigella flexneri serotype 2a O antigen antibodies following immunization or infection. Vaccine 1996; 14: 1062–1068.
6.Kotloff, KL, et al. A modified Shigella volunteer challenge model in which the inoculum is administered with bicarbonate buffer: clinical experience and implications for Shigella infectivity. Vaccine 1995; 13: 1488–1494.
7.Black, RE, et al. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. Journal of Infectious Disease 1987; 155: 1260–1265.
8.Taylor, DN, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clinical Infectious Diseases 2006; 42: 1283–1288.
9.DuPont, HL, et al. Immunity in shigellosis. II. Protection induced by oral live vaccine or primary infection. Journal of Infectious Disease 1972; 125: 12–16.
10.Herrington, DA, et al. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 1990; 8: 353–357.
11.DuPont, HL, Hornick, RB. Clinical approach to infectious diarrheas. Medicine (Baltimore) 1973; 52: 265–270.
12.Guerrant, R. Gastrointestinal infectious and food poisoning. In: Mandell, G, Douglas, R, Bennet, J, eds. Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1990, pp. 837–847.
13.Coster, TS, et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infection and Immunity 1999; 67: 3437–3443.
14.Kotloff, KL, et al. Evaluation of the safety, immunogenicity, and efficacy in healthy adults of four doses of live oral hybrid Escherichia coli-Shigella flexneri 2a vaccine strain EcSf2a-2. Vaccine 1995; 13: 495–502.
15.Ferreccio, C, et al. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. American Journal of Epidemiology 1991; 134: 614–627.
16.Cohen, D, Slepon, R, Green, MS. Sociodemographic factors associated with serum anti-Shigella lipopolysaccharide antibodies and shigellosis. International Journal of Epidemiology 1991; 20: 546–550.
17.Levine, MM, et al. Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. Nature Reviews Microbiology 2007; 5: 540–553.
18.Miller, FG, Grady, C. The ethical challenge of infection-inducing challenge experiments. Clinical Infectious Diseases 2001; 33: 1028–1033.
19.Rihl, M, et al. Infection and musculoskeletal conditions: reactive arthritis. Best Practice & Research: Clinical Rheumatology 2006; 20: 1119–1137.
20.Halvorson, HA, Schlett, CD, Riddle, MS. Postinfectious irritable bowel syndrome – a meta-analysis. American Journal of Gastroenterology 2006; 101: 1894–1899; quiz 942.
21.Thabane, M, Kottachchi, DT, Marshall, JK. Systematic review and meta-analysis: the incidence and prognosis of post-infectious irritable bowel syndrome. Alimentary Pharmacology and Therapeutics 2007; 26: 535–544.
22.Schwille-Kiuntke, J, et al. Post-infectious irritable bowel syndrome – a review of the literature. Zeitschrift für Gastroenterologie 2011; 49: 997–1003.
23.Hope, T, McMillan, J. Challenge studies of human volunteers: ethical issues. Journal of Medical Ethics 2004; 30: 110–116.
24.Munoz, C, et al. Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances. American Journal of Tropical Medicine and Hygiene 1995; 53: 47–54.
25.Tacket, CO, et al. Efficacy of bovine milk immunoglobulin concentrate in preventing illness after Shigella flexneri challenge. American Journal of Tropical Medicine and Hygiene 1992; 47: 276–283.
26.Kotloff, KL, et al. Safety, immunogenicity, and efficacy in monkeys and humans of invasive Escherichia coli K-12 hybrid vaccine candidates expressing Shigella flexneri 2a somatic antigen. Infection and Immunity 1992; 60: 2218–2224.
27.Mackowiak, PA, Wasserman, SS, Levine, MM. An analysis of the quantitative relationship between oral temperature and severity of illness in experimental shigellosis. Journal of Infectious Diseases 1992; 166: 1181–1184.
28.Van de Verg, L, et al. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infection and Immunity 1990; 58: 2002–2004.
29.DuPont, HL, et al. Inoculum size in shigellosis and implications for expected mode of transmission. Journal of Infectious Diseases 1989; 159: 1126–1128.
30.Levine, MM, et al. Studies with a new generation of oral attenuated shigella vaccine: Escherichia coli bearing surface antigens of Shigella flexneri. Journal of infectious Diseases 1977; 136: 577–582.
31.DuPont, HL, et al. The response of man to virulent Shigella flexneri 2a. Journal of Infectious Diseases 1969; 119: 296–299.
32.Levine, MM, et al. Pathogenesis of Shigella dysenteriae 1 (Shiga) dysentery. Journal of Infectious Diseases 1973; 127: 261–270.